Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 2/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7209957 | 0.88 | MMP13 (0.41) | MMP13RORCMMP1CHRM1CHRM3 | |
| SCHEMBL7290264 | 0.87 | MMP13 (0.55) | MMP13RORCMMP1CHRM1CHRM3 | |
| SCHEMBL7209955 | 0.84 | KAT6A (0.35) | MMP13RORCMMP1CHRM1CHRM3 | |
| SCHEMBL7290273 | 0.79 | MGLL (0.41) | MMP13RORCMMP1KAT6AACLY | |
| SCHEMBL7201008 | 0.76 | MMP13 (0.54) | MMP13MMP1MMP2MMP9MMP8 | |
| SCHEMBL7204063 | 0.75 | MMP13 (0.53) | MMP13MMP1MMP2MMP9 | |
| SCHEMBL7202562 | 0.74 | MMP13 (0.55) | MMP13MMP1MMP2MMP9KDM2B | |
| SCHEMBL7205953 | 0.74 | MMP13 (0.71) | MMP13MMP1MMP2MMP9MMP8 | |
| SCHEMBL7199642 | 0.72 | MMP13 (0.57) | MMP13MMP1MMP2MMP9MMP8 | |
| SCHEMBL7201763 | 0.72 | MMP13 (0.55) | MMP13MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | disclosed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | MMP13 4/4885RORC 2987/4885MMP1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.